Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has today moved forward to make the announcement regarding the appointment of Gary G. Gemignani who is expected to serve in the capacity of the new company’s Executive Vice President and Chief Financial Officer s well from April 17, 2017.
The new top executive will be stepping in the shoes of Bernard Denoyer, the former Senior Vice President who is as a matter of fact expected to continue rendering services in a number of areas, the transition process being one of them, until his eventual retirement set to take place on July 1, 2017.
Mr. Gemignani is a very highly experienced top executive after serving for quite a long period of time in the industry. In serving in the numerous top positions in both the biopharmaceutical and pharmaceutical companies, top and trusted sources reveal that he did quite much towards helping them forge forward in terms of business success as well as in the implementation of a number of the expansion plans.
His most recent position in Biodel, Inc where he is believed to have served very well in the capacity of a Chief Financial Officer and Chief Executive Officer. He will as a matter of fact be remembered for overseeing financing activities of the Company as well as the strategic planning and operations.
During his tenure in office, some trusted sources have come forward to reveal that he successfully spearheaded the reverse merger with Albireo as well as oversaw the management of a number of the corporate restructurings that targeted the strengthening and consolidation of Albireo’s overall financial standing.
The Chairman and Chief Executive Officer of Synergy Pharmaceuticals Inc, Gary S. Jacob has spoken on behalf of the company. He has expressed the great excitement upon welcoming this top executive to provide the company with his high experience and service that will see the company make a major leap forward in terms of business success.
Gary Gemignani in showing his appreciation pointed out that he was indeed excitement to be moving in at such a transformative period in the provider’s history and went ahead to promise that he would do much to see the company move forward to the highest levels of success.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
A new field of medicine needs attentionhttps://journaltranscript.com
Here are the reasons to invest in CMXC
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why